KCKenneth Cusi

Kenneth Cusi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kenneth Cusi has a total of 518 co-authors. Here are the top co-authors by number of shared publications:

  • Fernando Bril

    Division of Endocrinology, Diabetes and Metabolism University of Alabama at Birmingham Birmingham Alabama USA

    37 shared publications
  • Romina Lomonaco

    Division of Endocrinology, Diabetes and Metabolism, University of Florida College of Medicine, Gainesville, USA

    25 shared publications
  • Srilaxmi Kalavalapalli

    Division of Endocrinology, Diabetes and Metabolism, University of Florida College of Medicine, Gainesville, USA

    19 shared publications
  • Diana Barb

    Division of Endocrinology, Diabetes and Metabolism, University of Florida College of Medicine, Gainesville, USA

    18 shared publications
  • Zobair Younossi

    Beatty Liver and Obesity Research Program Inova Health System Falls Church Virginia USA

    10 shared publications
  • Beverly Orsak

    Diabetes Division, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

    9 shared publications

Latest Publications

  • Prediabetes and diabetes as drivers of fibrosis in MASLD: roles of obesity, adipose tissue dysfunction and insulin resistance

    by Eddison Godinez Leiva, Diana Barb, Srilaxmi Kalavalapalli, Andrea Ortiz Rocha, Nathaly Cuervo-Pardo, Anu Sharma, Enrique Valdez Saenz, Romina Lomonaco, Stephen A. Marangi, Shwetha S. Shetty, et al.

    Aims/hypothesis Prediabetes and type 2 diabetes have been associated with more severe metabolic dysfunction-associated steatotic liver disease (MASLD), but not all individuals have the same risk and the metabolic drivers remain incompletely understood. To understand why, we examined the roles of obesity, adipose tissue dysfunction and insulin resistance in the development of significant liver fibrosis (fibrosis stage ≥F2) in adults across the glycaemic spectrum. Methods We performed a prospective, cross-sectional study in a real-world setting of adults attending primary care or endocrinology/diabetes clinics. Transient elastography was used to diagnose steatosis (controlled attenuation parameter ≥274 dB/m) and clinically significant liver fibrosis (vibration-controlled transient elastography liver stiffness measurement ≥8.2 kPa). When ≥F2 was suspected, MR-based imaging or liver biopsy was used to improve stratification. MASLD and significant fibrosis were compared across glycaemic and BMI categories and severity of insulin resistance (HOMA-IR; predominantly hepatic) and adipose tissue insulin resistance (assessed by adipose tissue insulin resistance [Adipo-IR]). Results Among the 1446 participants, the prevalence of MASLD increased across glycaemic categories from 39% in participants with normoglycaemia, to 55% in those with prediabetes and to 68% in type 2 diabetes. Clinically significant fibrosis also increased across groups, being 1%, 6% and 12%, respectively. In prediabetes, clinically significant fibrosis was rare in lean or overweight individuals even though most had associated cardiometabolic risk factors, but this increased fourfold in individuals with obesity, particularly when associated with severe adipose tissue and systemic insulin resistance. Having obesity and type 2 diabetes had the highest prevalence of clinically significant fibrosis (16%), and again, mostly if associated with insulin resistance. Most participants with clinically significant fibrosis were in the highest quintiles of Adipo-IR or HOMA-IR (Q4–Q5). Conclusions/interpretation In a real-world cohort from primary care/endocrinology clinics, the prevalence of MASLD increased in a stepwise manner with glycaemic and BMI categories, but the prevalence of fibrosis did not increase in the same stepwise manner and remained rare in the absence of obesity, or in obesity without significant insulin resistance. Prediabetes was a risk factor for significant fibrosis mainly in individuals with obesity and significant insulin resistance. In the context of current guidelines, MASLD risk-stratification may be improved in primary care by establishing the metabolic impact of obesity/diabetes (i.e. assessing insulin resistance by HOMA-IR). Graphical Abstract

  • Using Homeostatic Model Assessment of Insulin Resistance to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease Risk Stratification in Individuals With Type 2 Diabetes From Primary Care and Endocrinology Settings

    by Nathaly Cuervo-Pardo, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, Diana Barb, Anu Sharma, Jens Rosenberg, Fernando Bril, Margery A. Connelly, Joseph R. Grajo, et al.

  • Open Access

    Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS ‐3 MRI

    by Kenneth Cusi, Amalia Gastaldelli, Laura Fernández Landó, Palash Sharma, Amelia Torcello‐Gómez, Ángel Rodríguez

    The patatin‐like phospholipase 3 (PNPLA3) I148M genetic variant is highly associated with steatotic liver disease. In the SURPASS‐3 MRI substudy, tirzepatide significantly reduced liver fat content (LFC) versus insulin degludec in insulin‐naïve patients with type 2 diabetes with metabolic dysfunction‐associated steatotic liver disease. The influence of PNPLA3 I148M allele on changes in LFC in response to tirzepatide is unknown. This post hoc analysis evaluated changes in MRI‐assessed LFC and cardiometabolic parameters by presence (genotypes GG and CG) or absence (genotype CC) of the PNPLA3 I148M allele after 52‐week treatment. Tirzepatide‐treated participants experienced significant reductions in LFC, weight, HbA 1c , and overall greater improvement in lipids and liver enzymes regardless of the presence of PNPLA3 I148M allele. Findings were consistent across genotype subgroups. In this exploratory analysis, the presence of PNPLA3 I148M allele did not seem to affect tirzepatide‐induced improvement in LFC and several cardiometabolic parameters in patients with type 2 diabetes. Trial Registration: ClinicalTrials.gov identifier: NCT03882970

  • Open Access

    High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics

    by Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, Anu Sharma, Diana Barb, Nathaly Cuervo‐Pardo, Kelly Y. Chun, Toni R. Prezant, Margery A. Connelly, Jens T. Rosenberg, et al.

    Aims: Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+ is a recently approved serum‐based test combining two biomarkers (miR‐34a‐5p and YKL‐40) to identify at‐risk MASH (i.e., MASH and significant fibrosis). Objective: To assess the prevalence of at‐risk MASH by NIS2+ in individuals from primary care or endocrinology clinics. Materials and Methods: 798 participants recruited from outpatient clinics were risk‐stratified by NIS2+ into low‐risk, intermediate‐risk or having at‐risk MASH (NIS2+ score < 0.46, ≥ 0.46 and < 0.68 or ≥ 0.68, respectively). Presence of steatosis (CAP ≥ 288 dB/m) and clinically significant liver fibrosis (VCTE‐ ≥ 8.0 kPa) was established by transient elastography (FibroScan). Results: At‐risk MASH affected 29% of individuals with both obesity and T2D compared to 3% of those without either condition ( p < 0.001). People with at‐risk MASH, compared to those at low‐risk, more often had steatosis (81% vs. 40%), clinically significant fibrosis (42% vs. 5%), AST or ALT ≥ 40 IU/L, hepatic insulin resistance (by HOMA‐IR) and adipose tissue insulin resistance (by adipo‐IR) (all p < 0.001). NIS2+ strongly correlated with diagnosis of at‐risk MASH by FAST ( r = 0.67; p < 0.001), as well as CK‐18, ALT and AST and liver fibrosis by VCTE‐LSM (all p < 0.001). Conclusion: The prevalence of at‐risk MASH is high in individuals with obesity and T2D attending outpatient primary care and endocrinology clinics. Their progression to cirrhosis may be prevented with early risk‐stratification and timely intervention.


  • Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams

    by Anastasia-Stefania Alexopoulos, Kenneth Cusi

    Metabolic dysfunction–associated steatotic liver disease (MASLD) affects the majority of individuals with diabetes and severe obesity, and is one of the most common indications for liver transplantation in the U.S. Emerging evidence underscores the synergistic and detrimental impact of alcohol and metabolic disease on liver and overall health. In 2023, the nomenclature for steatotic liver disease was revised to include a new subcategory known as MetALD (metabolic dysfunction– and alcohol-associated liver disease), which acknowledges alcohol use as a cofactor in liver injury alongside metabolic risk factors. This review offers key insights into the role of alcohol use as both a direct hepatotoxin and an indirect contributor to insulin resistance, dyslipidemia, and obesity. Notably, even light-to-moderate alcohol intake may hasten MASLD progression to cirrhosis and hepatocellular carcinoma, especially in individuals with existing metabolic disease, and can worsen cardiovascular disease risk. MetALD is associated with increased all-cause, cancer-related, and liver-related mortality in comparison with MASLD, reinforcing the importance of accurate alcohol assessment in managing diabetes and obesity. Diagnosis now requires stratifying alcohol use and integrating tools such as the Alcohol Use Disorders Identification Test (AUDIT) questionnaire and phosphatidylethanol testing. The caveats and use of these tools in clinical practice are discussed. Management strategies for MASLD focus on lifestyle changes, weight loss, and medications such as glucagon-like peptide 1 receptor agonists, with emerging evidence suggesting that these agents may also reduce alcohol consumption. However, treatment data on MetALD are limited. This review offers practical guidance for health care professionals on how to integrate alcohol use into existing, recommended MASLD care pathways.


  • Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption

    by Fernando Bril, Sean C Forbes, Srilaxmi Kalavalapalli, Kenneth Cusi

    Objective: This study compared in vivo changes in hepatic phosphate metabolites using phosphorus magnetic resonance spectroscopy (31P-MRS) in patients with vs without metabolic dysfunction-associated steatotic liver disease (MASLD) after oral fructose consumption. Methods: Thirty-seven overweight or obese patients without diabetes underwent a 2-hour oral glucose tolerance test, a fasting liver proton magnetic resonance spectroscopy, and a 31P-MRS before and during 60 minutes after an oral 75-gram fructose challenge. Results: Before fructose consumption, there were no differences in ATP, phosphomonoesters (PME), or phosphodiesters between groups. After fructose, patients without MASLD had a rapid increase in PME (from 15.5 ± 4.8 to 19.3 ± 5.1 within 15 minutes, P = .033). In these patients, inorganic phosphate (Pi) decreased during the first 30 minutes but then increased, leading to higher than baseline levels (from 10.2 ± 1.9 to 11.8 ± 2.8, P = .037). ATP significantly dropped in patients without MASLD within 15 minutes (from 21.8 ± 3.4 to 19.9 ± 4.0, P = .018), with persistently lower levels after 60 minutes (19.1 ± 4.1, P = .006 vs baseline). However, all these responses to oral fructose appeared blunted in patients with MASLD, with unchanged PME levels and only showing an Pi increase 45 minutes after fructose consumption. ATP levels showed a nonsignificant drop in the first 15 minutes with recovery of baseline levels at minute 30. Conclusion: Following fructose consumption, patients with MASLD exhibited distinct patterns of change in phosphate metabolites, reflecting differences in hepatic metabolic responses. These findings suggest altered hepatic metabolic handling of fructose in MASLD, which may have implications for disease progression.


  • Open Access

    Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes

    by Andrea Ortiz Rocha, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Diana Barb, Fernando Bril, Stephen A Marangi, Helena B Thomaides-Brears, Jens T Rosenberg, Nathaly Cuervo-Pardo, Romina Lomonaco, et al.

    Context Multiparametric magnetic resonance iron-corrected T1 mapping (cT1) may help identification and risk-stratification of steatohepatitis (MASH). Objective In type 2 diabetes, metabolic dysfunction-associated steatotic liver disease frequently advances to steatohepatitis with significant fibrosis and increased risk of developing cirrhosis. cT1 allows MASH risk-stratification by measuring liver disease activity (fibro-inflammation) but its association with cardiometabolic risk factors that drive liver disease progression in T2D (insulin resistance, lipotoxicity, and metabolic syndrome) remains unclear. Methods We recruited 109 participants with T2D from primary care settings who were classified into four groups according to cT1 and liver fat content (LiverMultiScan): (1) without steatosis; (2) steatosis only without MASH; (3) mild–moderate MASH (cT1 ≥ 800 to ≤875 ms); and (4) severe MASH (cT1 > 875 ms). We also measured insulin resistance (HOMA-IR), adipose tissue dysfunction (Adipo-IR, plasma adiponectin), and several noninvasive tests of MASH necroinflammation or fibrosis severity (NIS2+®, CK-18, FAST, and MRE). Results Higher MASH disease activity (cT1) was associated with more severe features of the metabolic syndrome as well as increased insulin resistance (HOMA-IR) and adipose tissue dysfunction (higher Adipo-IR and decreased adiponectin levels; all P < .01). Elevated cT1 correlated with worse hepatic necroinflammation (FAST, NIS2+®, and CK-18) and more severe steatosis and fibrosis (all P < .001). Conclusion In people with T2D, worse MASH disease activity (measured by cT1) is associated with unfavorable cardiometabolic risk factors that are known to drive liver disease progression. Use of cT1 in this population may help early identification of at-risk individuals who would benefit from earlier aggressive intervention in primary care.


  • Open Access

    Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort

    by Josep Le, María M. Malag, Marcelino Bermúdez-L, Jos, Reinald Pamplona, Gerard Torres, Dídac Mauricio, Eva Castro, Elvira Fern, Assumpta Caix, et al.

    Introduction: Advanced liver fibrosis, a key complication of metabolic dysfunction-associated steatotic liver disease, has been increasingly linked to extrahepatic conditions, including type 2 diabetes, obesity, and cardiovascular disease. However, the specific association of liver fibrosis in the development and progression of subclinical atheromatous disease across vascular territories remains poorly understood. This study evaluates the utility of two non-invasive indices to predict liver fibrosis and their associations with subclinical atheromatous plaque burden and distribution. Methods: Atheromatous plaque burden (plaque presence, number, and total area) was assessed in the carotid and femoral territories via ultrasonography in 3,981 middle-aged participants without known cardiovascular disease, diabetes, or liver disease from the ILERVAS cohort (ClinicalTrials.gov Identifier: NCT03228459). The fibrosis-4 (FIB-4) and the NAFLD Fibrosis Score (NFS) were evaluated. FIB-4 risk categories were defined as low (2.67). Results: Participants in the intermediate and high-risk FIB-4 categories exhibited a higher prevalence of carotid atheromatous disease (56.8% vs. 49.5%, p<0.001), a greater number of plaques (p<0.001), and a larger total plaque area (p=0.007). Multivariable analyses confirmed FIB-4 as an independent predictor of carotid plaque burden (OR: 1.14, 95% CI 1.05-1.24, p=0.003), even adjusting for traditional cardiovascular risk factors. Moving from low to high FIB-4 cut-offs was associated with 12.6% higher odds of carotid atherosclerosis. NFS was also independently associated with carotid atheromatosis (OR 1.10, 95% CI 1.05–1.15, p<0.001). No significant associations were found in the femoral territory for either index. Conclusions: Estimated liver fibrosis, particularly FIB-4, is a valuable marker for identifying carotid subclinical atherosclerosis in populations without known liver disease. These findings highlight the importance of vascular territory-specific evaluations and support their utility in integrated liver and cardiovascular risk assessment strategies.